What is this study trying to find out about bone and joint infections?

This study is observing adverse events in patients who have had phage therapy for bone or joint infections. Researchers want to know if these events are due to surgery, antibiotics, or the phage treatment. Hospices Civils de Lyon is leading this research to better understand treatment safety.

Who may be eligible for this bone and joint infection clinical trial?

Adults who have had bone, joint, or implant infections treated with phage therapy and experienced adverse events may be eligible. Both males and females can participate. Please review eligibility criteria for more details.

Is there any cost to participate in this bone and joint infection clinical trial?

Study-related care, including data collection and review, is provided at no cost. However, personal travel expenses or other costs are not guaranteed to be covered and may vary. Participants should plan accordingly.

Actively Recruiting

All Genders

ID04724603

Retrospective Study on Safety of Phage Therapy for Bone, Joint, or Implant Infections

Led by Hospices Civils de Lyon · Updated on 2023-04-13

Participants Needed

Research Sites

213 weeks

Total Duration

AI-Summary

What this Trial Is About

This research aims to understand the cause of adverse events in patients treated with phage therapy for bone, joint, or implant infections. The study investigates whether these adverse effects are related to surgery, antibiotic treatment, or the phage therapy itself. It is an observational study led by Hospices Civils de Lyon. Patients included in this study are those who have experienced an adverse event after receiving phage therapy for their infection. The study does not involve new treatments or interventions but observes and collects data on past adverse events associated with phage therapy, surgery, or antibiotic use. Participants medical records will be reviewed to identify the rate and types of adverse events occurring within one year after treatment. The study will assess which events are linked specifically to surgery, antibiotic therapy, or phage therapy. This information will help researchers understand the safety profile of phage therapy in these infections.

CONDITIONS

Brief Title

Phage Safety Retrospective Cohort Study

Who Can Participate

All Genders

Eligibility Criteria

You may qualify if you...

Patients having had a bone, joint, or implant infection treated by phagotherapy
Patients having experienced an adverse event after phagotherapy

You will not qualify if you...

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - 1 year

Participants who have had phagotherapy for bone, joint, or implant infection and experienced adverse events are observed to assess the rate and type of adverse events over time.